文献速递临床试验与 GCP

跨诊断睡眠干预对伴有抑郁、双相障碍或注意缺陷障碍的门诊睡眠问题患者的疗效:随机对照试验研究方案

The efficacy of a transdiagnostic sleep intervention for outpatients with sleep problems and depression, bipolar disorder, or attention deficit disorder: study protocol for a randomized controlled trial.
PubMed 文献 · Trials · 2024-01-16

本研究为随机对照试验,纳入88例伴有失眠、昼夜节律障碍或嗜睡等睡眠问题的双相障碍、单相抑郁或注意缺陷障碍门诊患者,随机分配至接受6次跨诊断睡眠治疗组或接受1次睡眠卫生教育对照组,主要结局为匹兹堡睡眠质量指数变化,研究于2022年启动,入组持续至2024年中。

要点

  • 跨诊断睡眠干预组接受6次治疗,对照组接受1次睡眠卫生教育。
  • 主要结局为匹兹堡睡眠质量指数评估的主观睡眠质量变化。
  • 次要结局包括客观与主观睡眠效率、入睡潜伏期、入睡后觉醒时间等。

核心结论

  • 主要假设是跨诊断睡眠干预与对照组相比可改善睡眠质量;次要假设是干预可增加主观和客观睡眠效率、减少入睡潜伏期、入睡后觉醒时间、觉醒次数和失眠严重程度,并改善幸福感、个人康复、工作能力和睡眠药物消耗。
  • 研究结果可能对精神障碍共病睡眠问题患者额外治疗方案的开发和实施产生影响。

研究设计与样本

  • 随机对照试验,纳入88例伴有失眠、昼夜节律障碍或嗜睡等睡眠问题的双相障碍、重性抑郁或注意缺陷障碍门诊患者。
  • 患者被分配至接受6次跨诊断睡眠治疗组或接受1次睡眠卫生教育对照组。
  • 评估在基线、第2周和6周后进行,所有患者在整个6周研究期间持续进行体动记录仪监测。
  • 研究于2022年启动,入组期持续至2024年中。
  • 试验注册于ClinicalTrials.gov,注册号NCT05406414,注册日期2022年6月6日。

关键数值与推荐

  • 主要结局为匹兹堡睡眠质量指数评估的主观睡眠质量变化。
  • 次要结局包括基于体动记录仪和睡眠日记的睡眠效率、入睡潜伏期、入睡后觉醒时间、夜间觉醒次数变化,失眠严重指数,WHO-5幸福感指数,INSPIRE-O个人康复,工作能力指数,以及睡眠日记记录的睡眠药物消耗。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Patients with mental disorders have a higher prevalence of sleep problems than the general population. Sleep problems may include insomnia, circadian rhythm disorders, or hypersomnia. A transdiagnostic approach combining cognitive behavioral therapy for insomnia (CBT-I) with chronotherapy addressing a broad range of sleep problems has shown promising results in a limited number of studies. The aim of the study is to investigate the efficacy of a transdiagnostic sleep intervention for patients with sleep problems comorbid to bipolar disorder, unipolar depression, or attention deficit disorders. The primary hypothesis is that the intervention improves sleep quality compared with a control group. The secondary hypotheses are that the intervention increases subjective and objective sleep efficiency, reduces sleep onset latency, wake after sleep onset, number of awakenings, and severity of insomnia; and that it improves well-being, personal recovery, work ability, and consumption of sleep medication compared with a control group. METHODS: The study is a randomized controlled trial enrolling 88 outpatients with bipolar disorder, major depression, or attention deficit disorder with symptoms of various sleep problems (insomnia, circadian rhythm disorders, or hypersomnia). Patients are allocated to either an intervention group receiving six sessions of transdiagnostic sleep treatment or to a control group receiving a single session of sleep hygiene education. Assessments are made at baseline, at week two, and after 6 weeks in both groups. Actigraphy is performed continuously throughout the 6-week study period for all patients. The primary outcome is changes in the subjective appraisal of sleep quality (Pittsburgh Sleep Quality Index). The secondary outcomes are changes in sleep efficiency, sleep onset latency, wake after sleep onset, number of nocturnal awakenings (based on actigraph and sleep diary data), changes in insomnia severity (Insomnia Severity Index), well-being (WHO-5 Well-Being Index), personal recovery (INSPIRE-O), work ability (Work Ability Index), and consumption of sleep medication (sleep-diaries). DISCUSSION: The study was initiated in 2022 and the inclusion period will continue until mid-2024. The results may have implications for the development and implementation of additional treatment options for patients with mental disorders and comorbid sleep problems. TRIAL REGISTRATION: ClinicalTrials.gov. NCT05406414. Registered on June 6, 2022.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Kragh M, Dyrberg H, Speed M, et al. The efficacy of a transdiagnostic sleep intervention for outpatients with sleep problems and depression, bipolar disorder, or attention deficit disorder: study protocol for a randomized controlled trial. Trials. 2024. PMID: 38229181. doi:10.1186/s13063-024-07903-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。